NWI Management LP Buys 25,540 Shares of Insmed, Inc. $INSM

NWI Management LP increased its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 2.6% in the first quarter, HoldingsChannel reports. The firm owned 1,014,000 shares of the biopharmaceutical company’s stock after buying an additional 25,540 shares during the quarter. Insmed makes up approximately 9.4% of NWI Management LP’s holdings, making the stock its 2nd biggest holding. NWI Management LP’s holdings in Insmed were worth $165,809,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in INSM. Norges Bank purchased a new position in Insmed in the 4th quarter valued at about $506,625,000. RTW Investments LP grew its holdings in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after buying an additional 1,758,321 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Insmed in the second quarter valued at approximately $153,389,000. State Street Corp raised its position in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after buying an additional 1,217,390 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after buying an additional 1,140,524 shares during the period.

Wall Street Analyst Weigh In

INSM has been the topic of a number of analyst reports. Wells Fargo & Company raised their target price on shares of Insmed from $160.00 to $161.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. BMO Capital Markets started coverage on Insmed in a report on Monday, July 20th. They issued an “outperform” rating and a $192.00 price target for the company. Roth Capital reissued a “buy” rating on shares of Insmed in a research note on Monday, June 8th. Guggenheim restated a “buy” rating and set a $207.00 price objective on shares of Insmed in a report on Friday, July 10th. Finally, Royal Bank Of Canada decreased their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $209.35.

Insmed Trading Down 2.8%

Shares of INSM stock opened at $98.60 on Friday. The firm’s 50-day simple moving average is $104.68 and its 200-day simple moving average is $131.02. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75. The firm has a market cap of $21.37 billion, a P/E ratio of -17.15 and a beta of 0.78.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period in the previous year, the firm earned ($1.42) earnings per share. Insmed’s revenue was up 229.7% compared to the same quarter last year. As a group, equities analysts forecast that Insmed, Inc. will post -2.43 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This trade represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. The trade was a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 54,590 shares of company stock worth $5,793,738 in the last 90 days. Company insiders own 2.10% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.